I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Docket No.: ZIPH-009-102

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

NOV is

Patent Application of:

l et al.

Application No.: 10/686,809

Filed: October 17, 2003

INDOLYL-3-GLYOXYLIC ACID For:

DERIVATIVES HAVING

THERAPEUTICALLY VALUABLE

PROPERTIES

Confirmation No.: 8786

Art Unit: 1614

Examiner: J. D. Anderson

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (SIDS)

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

This Supplemental Information Disclosure Statement is filed before the mailing date of a first Office Action after the filing of a Request for Continued Examination under 37 CFR 1.114 (37 CFR 1.97(b)(4)).

The Examiner is advised that the following applications, listed in the table below, contain subject matter that may be related to the pending claims in the present application. In particular, Applicants would like to draw the Examiner's attention to the fact that substantive examination may have occurred in this application, and Applicants invite the Examiner to review any Office Actions that have issued or will issue in this case. At the Examiner's request, we will provide copies of any Office Actions and/or responses to Office Actions that have issued in this application. By bringing these applications to the Examiner's attention, Applicants do not waive the confidentiality provisions of 35 U.S.C. 122.

Application No.: 10/686,809 Docket No.: ZIPH-009-102

Application Number 10/309,204	Filing Date December 4, 2002	Examiner's Initial and Date	
		/JDA/	01/25/2008
11/894,729	August 20, 2007	/JDA/	01/25/2008
11/894,591	August 20, 2007	/JDA/	01/25/2008

In accordance with 37 CFR 1.97(g), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Supplemental Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Supplemental Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 18-1945, under Order No. ZIPH-009-102.

Dated: November 9, 2007

Respectfully submitted,

Maya Ascobar, Ph.D.

Registration No.: 56,346

ROPES & GRAY LLP

One International Place

Boston, Massachusetts 02110

(617) 951-7000

(617) 951-7050 (Fax)

Attorneys/Agents For Applicant